Here we provide you with news articles, blogs and tweets on the key aspects of our bioinformatics and drug resistance work.

In this new section of the website, we disseminate printed and online media coverage of our work and its application in everyday life.

News Latest News


The 2012 Southern African ARV drug resistance testing guidelines

Share - 2013-01-13

Antiretroviral therapy (ART) has converted HIV infection from an almost universally fatal illness to a chronic manageable disease. Adherence to therapy is essential for full viral suppression and optimal immune reconstitution.

If antiretroviral (ARV) drug levels are suboptimal, the risk of developing ARV drug resistance is high due to the high rate of HIV replication and the lack of proofreading capacity in the viral reverse transcriptase enzyme. Continuation of a failing ART regimen can affect both the treated individual and the community, as resistant viral strains can be transmitted to other persons.

Resistance can be minimised by uninterrupted supply of medication, scientifically sound prescribing practices, long-term adherence support, viral load (VL) monitoring, and rapid responses to demonstrated virological failure with timeous changes of therapy. The Southern African HIV Clinicians Society developed consensus guidelines for HIV resistance testing that consider international best practice and the financial constraints encountered in southern Africa.

The guidelines, presented here, are based on the levels of resistance in the community as reported in the 2012 World Health Organization (WHO) HIV drug resistance report. The North American and British resistance testing guidelines, although ideal, are not affordable nor applicable in most southern African situations. These guidelines are aimed at southern African clinicians who manage individuals with HIV infection in both the private and public sectors in our region.


Publication cited

The 2012 southern African ARV drug resistance testing guidelines. Conradie F, Wilson D, Basson A, de Oliveira T, Hunt G, Joel D, Papathanasopoulos M, Preiser W, Klausner J, Spencer D, Stevens W, Venter F, van Vuuren C, S Afr J HIV Med (2012), 13(4):162-167.

15 minutes, All news...

Why KRISP? KRISP challenges the status quo to create a scientific environment in South Africa that drives innovations & reverses the brain drain.
From Why KRISP?, date: 2017-12-31

Integrating Assisted Partner Services and Phylogenetics for HIV and Hepatitis C Prevention in Nairobi
From KRISP Talks, date: 2017-11-17

Real-time genomic epidemiology for outbreak response: Lessons and insights from the 2014-2016 Ebola virus epidemic
From KRISP Talks, date: 2017-11-16
15 minutes, All news...

Page design updated by Tulio de Oliveira, 2015